IP Library › Granted Patent US 12,318,358
Granted Patent B2
US 12,318,358 · App. 16/630,114 · Granted Jun 3, 2025

Probenecid for use in treating epileptic diseases, disorders or conditions

Inventors: Nathalie Rouach (Paris, FR); Eléna Dossi (Boulogne-Billancourt, FR); Gilles Huberfeld (Garches, FR)
Assignees: PARIS SCIENCES ET LETTRES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE); SORBONNE UNIVERSITÉ; APHP (ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS); COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (CEA); UNIVERSITÉ PARIS CITÉ
A61K31/195A61P25/08A61K9/0019A61K9/0053
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,318,358
App. No.
16/630,114
Granted
Jun 3, 2025
Kind
B2
Abstract

Probenecid or a pharmaceutical acceptable salt thereof for use in the treatment of a neurological disorder in a subject in need thereof, wherein administration of probenecid or a pharmaceutical acceptable salt thereof controls clinical or electrographic seizures in the subject. Preferably, the neurological disorder is an epileptic disease, disorder or condition.

Claims (13)

1. A method for treating focal epilepsy in a human subject in need thereof , said focal epilepsy being characterized by an occurrence of spontaneous and recurrent focal seizures, the method comprising administering to the human subject a pharmaceutical composition consisting essentially of probenecid or a pharmaceutical acceptable salt thereof, wherein probenecid or the pharmaceutical acceptable salt thereof controls focal seizures in said human subject, and wherein probenecid or the pharmaceutical acceptable salt thereof is the only therapeutic agent administered to said human subject.

2. The method according to claim 1 , wherein the focal epilepsy is selected from the group consisting of familial epilepsy, genetic epilepsy, structural/metabolic epilepsy and epilepsies with unknown cause.

3. The method according to claim 1 , wherein the focal epilepsy is brain tumor-related epilepsy.

4. The method according to claim 1 , wherein the focal epilepsy is a malformation of cortical development (MCD)-related epilepsy.

5. The method according to claim 1 , wherein the focal epilepsy is a neurodegenerative-related epilepsy.

6. The method according to claim 1 , wherein the focal epilepsy is a dysimmune epilepsy.

7. The method according to claim 1 , wherein the human subject is suffering from a treatment-resistant focal epilepsy.

8. The method according to claim 1 , wherein said human subject is a child.

9. The method according to claim 1 , wherein said human subject is an adult.

10. The method according to claim 1 , wherein probenecid or the pharmaceutical acceptable salt thereof is administered to the human subject at a dose ranging from 1 mg/kg/day to 100 mg/kg/day.

11. The method according to claim 1 , wherein probenecid or the pharmaceutical acceptable salt thereof is administered orally or by injection.

12. The method according to claim 1 , wherein probenecid or the pharmaceutical acceptable salt thereof is comprised within a pharmaceutical composition also comprising a pharmaceutically acceptable carrier or diluent.

13. The method according to claim 1 , wherein probenecid or the pharmaceutical acceptable salt thereof is comprised within a medicament.

Assignments (3)
CHANGE OF NAME Recorded Jun 17, 2022
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 060530/0623 →
CHANGE OF NAME Recorded Jan 19, 2022
From: PARIS SCIENCES ET LETTRES - QUARTIER LATIN
To: PARIS SCIENCES ET LETTRES
Reel/Frame 058772/0593 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2020
From: ROUACH, NATHALIE; DOSSI, ELÉNA; HUBERFELD, GILLES
To: PARIS SCIENCES ET LETTRES - QUARTIER LATIN; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE); SORBONNE UNIVERSITÉ; APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS); COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (CEA); UNIVERSITE DE PARIS
Reel/Frame 052000/0726 →
Priority Claims (1)
EP 17305934 · Jul 13, 2017 · regional
Continuity (1)
Related Publication 20200163916A1 · May 28, 2020
References Cited (74)
US 4657899A · Rzeszotarski et al. · 1987 [cited by applicant]
US 4705781A · Boast · 1987 [cited by applicant]
US 4746653A · Hutchison et al. · 1988 [cited by applicant]
US 4761405A · Rzeszotarski et al. · 1988 [cited by applicant]
US 4812458A · Honoré et al. · 1989 [cited by applicant]
US 4863953A · Leeson et al. · 1989 [cited by applicant]
US 4889855A · Jacobsen et al. · 1989 [cited by applicant]
US 4898854A · Hutchison et al. · 1990 [cited by applicant]
US 4902687A · Ornstein · 1990 [cited by applicant]
US 4902695A · Ornstein · 1990 [cited by applicant]
US 4904681A · Cordi et al. · 1990 [cited by applicant]
US 4906621A · Hutchison et al. · 1990 [cited by applicant]
US 4918064A · Cordi et al. · 1990 [cited by applicant]
US 4925867A · Baker et al. · 1990 [cited by applicant]
US 4960786A · Salituro et al. · 1990 [cited by applicant]
US 4968678A · Ornstein · 1990 [cited by applicant]
US 5489579A · McDonald · 1996 [cited by examiner]
US 5627168A · Bigge · 1997 [cited by examiner]
EP 0260467B1 · 1988 [cited by applicant]
EP 0275820B1 · 1988 [cited by applicant]
EP 0302826A2 · 1989 [cited by applicant]
EP 0303387B1 · 1989 [cited by applicant]
EP 0315959B1 · 1989 [cited by applicant]
EP 0342558B1 · 1989 [cited by applicant]
EP 0348872B1 · 1990 [cited by applicant]
EP 0364996A2 · 1990 [cited by applicant]
EP 0374534B1 · 1990 [cited by applicant]
EP 0377112B1 · 1990 [cited by applicant]
EP 0378134A2 · 1990 [cited by applicant]
EP 0386839B1 · 1990 [cited by applicant]
EP 0387867B1 · 1990 [cited by applicant]
EP 0391850B1 · 1990 [cited by applicant]
EP 0396124A2 · 1990 [cited by applicant]
EP 0418863B1 · 1991 [cited by applicant]
EP 0420806B1 · 1991 [cited by applicant]
EP 0501378A1 · 1992 [cited by applicant]
EP 0603301B1 · 1994 [cited by applicant]
GB 2104078B · 1985 [cited by applicant]
GB 2157685A · 1985 [cited by applicant]
GB 2156818B · 1987 [cited by applicant]
GB 2198134B · 1990 [cited by applicant]
GB 2231048A · 1990 [cited by applicant]
GB 2201676B · 1991 [cited by applicant]
JP 586027A · 1993 [cited by applicant]
JP 6510544A · 1994 [cited by applicant]
JP 7504890A · 1995 [cited by applicant]
WO 9304688A1 · 1993 [cited by applicant]
WO 9312780A1 · 1993 [cited by applicant]
Neurological disorders, John Hopkins Medicine, https://www.hopkinsmedicine.org/health/conditions-and-diseases/neurological-disorders, accessed Jul. 31, 2021. [cited by examiner]
Enna et al. Journal of Neurochemistry 1977, 28, 1121-1124. [cited by examiner]
Moroni et al. Journal of Neurochemistry 1988, 51, 177-180. [cited by examiner]
Vecsei et al. Brain Research Bulletin 1992, 28 (2), 233-238. [cited by examiner]
Thurman et al. Epilepsia 2011, 52 (Suppl. 7), 2-26. [cited by examiner]
Silverman et al. Am J Physiol Cell Physiol 2008 295 (3) C761-C767. [cited by examiner]
Santiago et al. PLOS One 20011, 6 (9), e25178, p. 1-8. [cited by examiner]
Bhaskaracharya et all. PLOS One 2014, 9 (3), e93058, pp. 1-8. [cited by examiner]
Li et al. Oncotarget 2017, 8(4), 6883. [cited by examiner]
Fauser et al. Brain 2006, 129, 1907-1916. [cited by examiner]
Anand K. Sarma, et al., “Medical management of epileptic seizures: challenges and solutions”, Neuropsychiatric Disease and Treatment, 2016, vol. 12, pp. 467-485 (19 pgs.). [cited by applicant]
Stephen M. Berge, et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, Jan. 1977, vol. 66, No. 1, pp. 1-19 (19 pgs.). [cited by applicant]
Anne T. Berg, et al., “Revised terminology and concepts for organization of seizures and epilepsies: Report of the LAE Commission on Classification and Terminology, 2005-2009”, Epilepsia, 2010, vol. 51, No. 4, pp. 676-6… [cited by applicant]
Elena Dossi, et al., “Multi-electrode Array Recordings of Human Epileptic Postoperative Cortical Tissue”, Journal of Visualized Experiments (JOVE), Oct. 2014, vol. 92, e51870, pp. 1-9 (9 pgs.), at URL: http://www.jove.c… [cited by applicant]
H. Németh, et al., “Kynurenine administered together with probenecid markedly inhibits pentylenetetrazol-induced seizures. An electrophysiological and behavioural study”, Neuropharmacology, 2004, vol. 47, No. 6, pp. 916… [cited by applicant]
Charles P. Taylor, et al., “Probenecid pretreatment enhances anticonvulsant action of NBQX in mice”, European Journal of Pharmacology, 1992, vol. 213, No. 1, pp. 151-153 (3 pgs.). [cited by applicant]
Rachel A. Bergstrom, et al., “Automated identification of multiple seizure-related and interictal epileptiform event types in the EEG of mice”, Science Reports, Mar. 21, 2013, vol. 3, No. 1483, pp. 1-8 (8 pgs.). [cited by applicant]
Matthias A. Hediger, et al., “Molecular Physiology of Urate Transport”, Physiology (Bethesda), Apr. 2005, vol. 20, pp. 125-133 (9 pgs.). [cited by applicant]
Ana Laura Colín-González, et al., “Probenecid : An Emerging Tool for Neuroprotection”, CNS & Neurological Disorders—Drug Targets, 2013, vol. 12, No. 7, pp. 1050-1065 (16 pgs.). [cited by applicant]
Alan C. Foster, et al., “Kynurenic Acid Blocks Neurotoxicity and Seizures Induced in Rats by the Related Brain Metabolite Quinolinic Acid”, Neuroscience Letters, 1984, vol. 48, pp. 273-278 (6 pgs.). [cited by applicant]
David W. Walker, et al., “Kynurenic Acid in Brain and Cerebrospinal Fluid of Fetal, Newborn, and Adult Sheep and Effects of Placental Embolization”, Pediatric Research, 1999, vol. 45, No. 6, pp. 820-826 (7 pgs.). [cited by applicant]
William Silverman, et al., “Probenecid, a gout remedy, inhibits pannexin 1 channels”, Am J Physiol Cell Physiol, 2008, vol. 295, No. 3, pp. C761-C767 (7 pgs.). [cited by applicant]
Weihong MA, et al., “Pharmacological Characterization of Pannexin-1 Currents Expressed in Mammalian Cells”, The Journal of Pharmacology and Experimental Therapeutics, 2009, vol. 328, No. 2, pp. 409-418 (10 pgs.). [cited by applicant]
Arthur Yuwiler, et al., “Is There a Probenecid Sensitive Transport System for Monoamine Catabolites at the Level of the Brain Capillary Plexus?”, Neurochemical Research, 1982, vol. 7, No. 10, pp. 1277-1285 (9 pgs.). [cited by applicant]
International Search Report dated Aug. 20, 2018, in connection with corresponding international Application No. PCT/EP2018/069092 (4 pgs.). [cited by applicant]
Gong, “The role of probenecid in the treatment of refractory epilepsy by reversing the expression of multidrug resistance-associated protein”, Journal of Stroke and Neuropathy, Dec. 2005, vol. 22 No. 6, 10 pages. [cited by applicant]